Global Sickle Cell Disease Treatment Market by Treatment Type (Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global sickle cell disease treatment market was valued at USD2.1 billion in 2017. It is expected to grow at 14.3% over the forecast period. Sickle cell disease (SCD), a hereditary blood disorder, is characterised by abnormal, rigid and sickle-shaped red cells (RBCs), which are caused by mutations in beta-globin. The severity of the disease can vary greatly from one person to another.
Different mutations in hemoglobin genes can lead to sickle cell anemia with genotypic or phenotypic variations. Around 20-25 million people are affected by inherited sickle cells. Every year, approximately 300,000 babies are born with the disease. People of African, Middle Eastern and South Asian descent are most likely to have sickle cell disease. The global market will be driven by several factors, including increased immigration and improved healthcare services.
Chronic SCD is currently treated with hydroxyurea and blood transfusions. A large percentage of patients become allergic to hydroxyurea. Patients who are not resistant to hydroxyurea have limited benefits, but there are long-term safety risks.
Patients who receive blood transfusions may be at risk for iron overload, blood-borne infection, fever, or allergic reactions. Around 20% of patients suffering from sickle cell disease are transfusion-dependent. BMT (bone marrow transplant) is the only treatment that may be curative. However, it is only recommended for a small number of patients.
Hydroxyurea was the FDA-approved drug to treat the disease. It was marketed under the names Droxia and Hydrea by Bristol-Myers Squibb, Addmedica, and Sicklos By Bristol-Myers Squibb. Endari, a treatment for severe complications of SCD in children and adults over 5 years old, was approved by FDA by Emmaus Life Sciences in July 2017. Endari was approved by FDA as the second drug.
Favorable government policies, increased awareness of hematological malignancies and increased investment are some of the reasons emerging markets like Nigeria, Ghana and South Africa, Brazil and Saudi Arabia will experience lucrative growth in the forecast period.
Treatment Insights
The only treatments currently available for sickle cell diseases are symptomatic relief and palliative. Patients under 16 years old are not eligible for bone marrow transplant as the only treatment for SCD. However, the risks associated with BMT in adult patients are high. Treatment generally involves blood transfusions, medication to reduce pain and prevent complications, as well as bone marrow transplant.
Endari and Hydroxyurea are the only approved drugs for SCD. The potential launch of promising pipeline candidates like voxelotor, crizanlizumab and rivipansel is expected to support the rapid growth in pharmacotherapy for sickle cell diseases treatment.
Blood transfusion was the most popular treatment for sickle cell disease, accounting for more than 44.0% of the market in 2017. Due to strong pipelines and promising drug launches, pharmacotherapy will be the dominant market by 2023.
Country Insights
With a market share of over 37.0%, the U.S. was the dominant country in the global sickle-cell anemia treatment market. France and the U.K were close behind. France will see a CAGR close to 14% in 2017, but the U.S. will continue to hold its lead position throughout the forecast period. This is due to the potential launch of new therapeutics, increased adoption of innovative therapies, large African-American populations, and high treatment costs.
The European migrant crisis, which has led to an increase in immigrant populations from Africa, South Asia and Western Asia, is a major driver of the market in EU5 nations. The seven largest markets will grow at a combined CAGR of over 13.0%. Meanwhile, the Rest of the World is forecast to grow at an estimated 15.0% CAGR during the forecast period.
Market Share Insights & Key Companies
Emmaus Medical, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer, Inc., and Novartis AG are some of the major players in the sickle-cell anemia treatment market. Endari's strong sales support Emmaus Medical, which is expected to be the dominant player in the market by 2023, will help Emmaus Medical dominate. Global Blood Therapeutics, Sancilio and Altemia have the potential for significant market share after the approvals of their pipeline candidates-voxelotors and Altemia.
Promising results have been also shown for late-stage pipeline drugs like Novartis' crizanlizumab or Pfizer’s rivipansel. The market will likely be positively affected by the launch of disruptive therapeutics like Modus Therapeutics’ Sevuparin or Prolong Pharmaceuticals’ Sanguinate. In the near future, the sickle cell disease market will see the introduction of gene therapies like bluebird bio's Lentiglobin and Bellicum Pharmaceuticals' BPX 501.
Sickle Cell Disease Treatment Market Report Scope
The Report Covers Certain Segments
This report forecasts revenue growth at the global, regional and country level and offers an analysis of industry trends in each sub-segment from 2017 through 2023. Grand View Research, Inc. analyzed the global sickle-cell disease market report by country and treatment.
-
The Treatment Outlook (Revenue USD Million, 2017-2023)
-
Transfusion of blood
-
Pharmacotherapy
-
Transplantation of bone marrow
-
-
Country Outlook (Revenue USD Million, 2017-2023)
-
The U.S.
-
The U.K.
-
Germany
-
Spain
-
Italy
-
France
-
Japan
-
These are the most frequently asked questions about this report
What are the top companies in the sickle cell disease treatment industry?b. Novartis AG, Pfizer Inc., bluebird bio, Inc., Global Blood Therapeutics, Inc., GlycoMimetics, Inc., F. Hoffmann-La Roche AG, Emmaus Life Sciences, Inc., Bristol-Myers Squibb, CRISPR Therapeutics are some of the key players in the global sickle-cell disease treatment market.
What is the size of the market for sickle cell disease treatment?b. Global sickle cell disease treatment market was valued at USD 0.8 Billion in 2019, and is forecast to grow to USD 1.0 Billion by 2020.
What are the market opportunities for sickle cell disease treatment?b. Market opportunities for global sickle cell disease treatment include high growth potential in emerging markets and the introduction cost-effective treatments.
What is the growth rate of sickle cell disease treatment markets?b. Global sickle cell disease treatment markets are expected to grow at a compound annual rate of 19.9% between 2020 and 2027, reaching USD 3.6 billion in 2027.
What are the market drivers of sickle cell disease treatment?b. The market for sickle-cell disease treatment is growing due to high unmet need, a strong pipeline of new sickle cell treatment drugs and an increase in government initiatives for the development novel therapies.
Up Market Research published a new report titled “Sickle Cell Disease Treatment Market research report which is segmented by Treatment Type (Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy), By Players/Companies CRISPR Therapeutics, F Hoffmann-La Roche AG, Inc, Bristol-Myers Squibb, Inc, bluebird bio, Inc, Global Blood Therapeutics, Emmaus Life Sciences, GlycoMimetics, Inc, Novartis AG, Pfizer Inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
| Report Attributes | Report Details |
| Report Title | Sickle Cell Disease Treatment Market Research Report |
| By Treatment Type | Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy |
| By Companies | CRISPR Therapeutics, F Hoffmann-La Roche AG, Inc, Bristol-Myers Squibb, Inc, bluebird bio, Inc, Global Blood Therapeutics, Emmaus Life Sciences, GlycoMimetics, Inc, Novartis AG, Pfizer Inc |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 245 |
| Number of Tables & Figures | 172 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Sickle Cell Disease Treatment Market Report Segments:
The market is segmented by Treatment Type (Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy).
Sickle Cell Disease Treatment Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Sickle Cell Disease Treatment Market
Overview of the regional outlook of the Sickle Cell Disease Treatment Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Sickle Cell Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Sickle Cell Disease Treatment Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Blood Transfusion
2. Bone Marrow Transplant
3. Pharmacotherapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Sickle Cell Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Sickle Cell Disease Treatment Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sickle Cell Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sickle Cell Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sickle Cell Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sickle Cell Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sickle Cell Disease Treatment Market Size & Forecast, 2018-2028
4.5.1 Sickle Cell Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Sickle Cell Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Sickle Cell Disease Treatment Market Analysis and Forecast by Treatment Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Treatment Type
5.1.2 Basis Point Share (BPS) Analysis by Treatment Type
5.1.3 Absolute $ Opportunity Assessment by Treatment Type
5.2 Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
5.2.1 Blood Transfusion
5.2.2 Bone Marrow Transplant
5.2.3 Pharmacotherapy
5.3 Market Attractiveness Analysis by Treatment Type
Chapter 6 Global Sickle Cell Disease Treatment Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Sickle Cell Disease Treatment Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Sickle Cell Disease Treatment Analysis and Forecast
8.1 Introduction
8.2 North America Sickle Cell Disease Treatment Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
8.6.1 Blood Transfusion
8.6.2 Bone Marrow Transplant
8.6.3 Pharmacotherapy
8.7 Basis Point Share (BPS) Analysis by Treatment Type
8.8 Absolute $ Opportunity Assessment by Treatment Type
8.9 Market Attractiveness Analysis by Treatment Type
Chapter 9 Europe Sickle Cell Disease Treatment Analysis and Forecast
9.1 Introduction
9.2 Europe Sickle Cell Disease Treatment Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
9.6.1 Blood Transfusion
9.6.2 Bone Marrow Transplant
9.6.3 Pharmacotherapy
9.7 Basis Point Share (BPS) Analysis by Treatment Type
9.8 Absolute $ Opportunity Assessment by Treatment Type
9.9 Market Attractiveness Analysis by Treatment Type
Chapter 10 Asia Pacific Sickle Cell Disease Treatment Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Sickle Cell Disease Treatment Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
10.6.1 Blood Transfusion
10.6.2 Bone Marrow Transplant
10.6.3 Pharmacotherapy
10.7 Basis Point Share (BPS) Analysis by Treatment Type
10.8 Absolute $ Opportunity Assessment by Treatment Type
10.9 Market Attractiveness Analysis by Treatment Type
Chapter 11 Latin America Sickle Cell Disease Treatment Analysis and Forecast
11.1 Introduction
11.2 Latin America Sickle Cell Disease Treatment Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
11.6.1 Blood Transfusion
11.6.2 Bone Marrow Transplant
11.6.3 Pharmacotherapy
11.7 Basis Point Share (BPS) Analysis by Treatment Type
11.8 Absolute $ Opportunity Assessment by Treatment Type
11.9 Market Attractiveness Analysis by Treatment Type
Chapter 12 Middle East & Africa (MEA) Sickle Cell Disease Treatment Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Sickle Cell Disease Treatment Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
12.6.1 Blood Transfusion
12.6.2 Bone Marrow Transplant
12.6.3 Pharmacotherapy
12.7 Basis Point Share (BPS) Analysis by Treatment Type
12.8 Absolute $ Opportunity Assessment by Treatment Type
12.9 Market Attractiveness Analysis by Treatment Type
Chapter 13 Competition Landscape
13.1 Sickle Cell Disease Treatment Market: Competitive Dashboard
13.2 Global Sickle Cell Disease Treatment Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 CRISPR Therapeutics
13.3.2 F Hoffmann-La Roche AG
13.3.3 Inc
13.3.4 Bristol-Myers Squibb
13.3.5 Inc
13.3.6 bluebird bio
13.3.7 Inc
13.3.8 Global Blood Therapeutics
13.3.9 Emmaus Life Sciences
13.3.10 GlycoMimetics
13.3.11 Inc
13.3.12 Novartis AG
13.3.13 Pfizer Inc
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Sickle Cell Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Sickle Cell Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Sickle Cell Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Sickle Cell Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Sickle Cell Disease Treatment Market Size & Forecast, 2018-2028
4.5.1 Sickle Cell Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Sickle Cell Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Sickle Cell Disease Treatment Market Analysis and Forecast by Treatment Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Treatment Type
5.1.2 Basis Point Share (BPS) Analysis by Treatment Type
5.1.3 Absolute $ Opportunity Assessment by Treatment Type
5.2 Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
5.2.1 Blood Transfusion
5.2.2 Bone Marrow Transplant
5.2.3 Pharmacotherapy
5.3 Market Attractiveness Analysis by Treatment Type
Chapter 6 Global Sickle Cell Disease Treatment Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Sickle Cell Disease Treatment Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Sickle Cell Disease Treatment Analysis and Forecast
8.1 Introduction
8.2 North America Sickle Cell Disease Treatment Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
8.6.1 Blood Transfusion
8.6.2 Bone Marrow Transplant
8.6.3 Pharmacotherapy
8.7 Basis Point Share (BPS) Analysis by Treatment Type
8.8 Absolute $ Opportunity Assessment by Treatment Type
8.9 Market Attractiveness Analysis by Treatment Type
Chapter 9 Europe Sickle Cell Disease Treatment Analysis and Forecast
9.1 Introduction
9.2 Europe Sickle Cell Disease Treatment Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
9.6.1 Blood Transfusion
9.6.2 Bone Marrow Transplant
9.6.3 Pharmacotherapy
9.7 Basis Point Share (BPS) Analysis by Treatment Type
9.8 Absolute $ Opportunity Assessment by Treatment Type
9.9 Market Attractiveness Analysis by Treatment Type
Chapter 10 Asia Pacific Sickle Cell Disease Treatment Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Sickle Cell Disease Treatment Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
10.6.1 Blood Transfusion
10.6.2 Bone Marrow Transplant
10.6.3 Pharmacotherapy
10.7 Basis Point Share (BPS) Analysis by Treatment Type
10.8 Absolute $ Opportunity Assessment by Treatment Type
10.9 Market Attractiveness Analysis by Treatment Type
Chapter 11 Latin America Sickle Cell Disease Treatment Analysis and Forecast
11.1 Introduction
11.2 Latin America Sickle Cell Disease Treatment Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
11.6.1 Blood Transfusion
11.6.2 Bone Marrow Transplant
11.6.3 Pharmacotherapy
11.7 Basis Point Share (BPS) Analysis by Treatment Type
11.8 Absolute $ Opportunity Assessment by Treatment Type
11.9 Market Attractiveness Analysis by Treatment Type
Chapter 12 Middle East & Africa (MEA) Sickle Cell Disease Treatment Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Sickle Cell Disease Treatment Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Sickle Cell Disease Treatment Market Size Forecast by Treatment Type
12.6.1 Blood Transfusion
12.6.2 Bone Marrow Transplant
12.6.3 Pharmacotherapy
12.7 Basis Point Share (BPS) Analysis by Treatment Type
12.8 Absolute $ Opportunity Assessment by Treatment Type
12.9 Market Attractiveness Analysis by Treatment Type
Chapter 13 Competition Landscape
13.1 Sickle Cell Disease Treatment Market: Competitive Dashboard
13.2 Global Sickle Cell Disease Treatment Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 CRISPR Therapeutics
13.3.2 F Hoffmann-La Roche AG
13.3.3 Inc
13.3.4 Bristol-Myers Squibb
13.3.5 Inc
13.3.6 bluebird bio
13.3.7 Inc
13.3.8 Global Blood Therapeutics
13.3.9 Emmaus Life Sciences
13.3.10 GlycoMimetics
13.3.11 Inc
13.3.12 Novartis AG
13.3.13 Pfizer Inc
Segments Covered in the Report
The global Sickle Cell Disease Treatment market has been segmented based on
By Treatment Type
The global Sickle Cell Disease Treatment market has been segmented based on
By Treatment Type
- Blood Transfusion
- Bone Marrow Transplant
- Pharmacotherapy
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- CRISPR Therapeutics
- F Hoffmann-La Roche AG
- Inc
- Bristol-Myers Squibb
- Inc
- bluebird bio
- Inc
- Global Blood Therapeutics
- Emmaus Life Sciences
- GlycoMimetics
- Inc
- Novartis AG
- Pfizer Inc
Our Clients
Related Reports
Some other reports from this category!
